Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology · Hemoglobin E-beta-thalassemia

Transfusion Needs: Understanding TDT vs. NTDT

At a Glance

In hemoglobin E-beta-thalassemia, TDT means regular transfusions are needed to support survival and growth, while NTDT means regular lifelong transfusions are not needed. The classification can change as anemia, growth, spleen size, symptoms, and complications evolve.

One of the most important aspects of an HbE/beta-thalassemia diagnosis is understanding that it is not a “one-size-fits-all” condition. Doctors do not classify the disease based on genetics alone, but rather by how it behaves in your body. This clinical behavior usually places a patient into one of two categories: Transfusion-Dependent Thalassemia (TDT) or Non-Transfusion-Dependent Thalassemia (NTDT) [1][2].

Transfusion-Dependent Thalassemia (TDT)

A person is classified as having TDT if they require regular blood transfusions—usually every 2 to 4 weeks—to survive, grow normally, and prevent severe complications [3][4].

In TDT, the body’s own red blood cell production is so ineffective that without donor blood, the anemia would become life-threatening. The goal of regular transfusions in TDT is to keep the “pre-transfusion” hemoglobin (the level just before the next bag of blood) around safe targets and suppress the bone marrow from overworking [3].

Non-Transfusion-Dependent Thalassemia (NTDT)

A person with NTDT can survive without regular, lifelong transfusions [1]. However, “non-transfusion-dependent” does not mean “transfusion-free.” People with NTDT may still need blood occasionally during “stress” events, such as:

  • Severe infections or illnesses [5].
  • Pregnancy [6].
  • Major surgery [5].
  • Periods of rapid growth or puberty [3].

The Spectrum and Clinical Decisions

Because HbE/beta-thalassemia is so variable, doctors sometimes use tools like the Mahidol score (or Thai score) as an optional aid to help describe severity. This score looks at several factors [7][8]:

  • Hemoglobin levels: How low does the blood count sit naturally?
  • Spleen size: Is the spleen enlarged?
  • Growth and development: Is the child reaching typical height and weight milestones?
  • Age at first symptoms: Did the anemia show up in infancy or later in childhood?

While a score helps group patients into mild, moderate, or severe categories, it is not a universal rulebook for starting transfusions. The decision relies on overall symptoms, bone changes, and hemoglobin trajectories. A “severe” NTDT patient might eventually be moved into the TDT category if their complications become too difficult to manage without regular blood [9][10].

Why the Classification Can Change

It is common for a child to start as NTDT but transition to TDT as they grow older. This shift often happens because of:

  • Increased Demand: As the body grows, it needs more oxygen and more blood than the marrow can provide [3].
  • Splenomegaly: The spleen acts as a filter for blood. In thalassemia, the spleen often becomes enlarged (splenomegaly) because it is working overtime to clear out damaged red blood cells. Over time, an overactive spleen can start destroying healthy donor blood or the body’s few healthy cells, making the anemia worse [11][12].

Risks of “Undertransfusion”

If a patient has severe anemia but is not receiving enough transfusions, the body tries to compensate in ways that can be harmful. This is often why a doctor will recommend moving from NTDT to TDT.

  • Skeletal Changes: When the bone marrow works too hard to make blood, it expands. This expansion can thin the bones (increasing the risk of fractures) or cause facial and skull bone changes associated with marrow expansion [13][14].
  • Extramedullary Hematopoiesis (EMH): When the bone marrow can’t keep up, the body tries to make blood in other places, like the liver, spleen, or even along the spine. These “masses” of blood-forming tissue can sometimes press on nerves, which is a medical emergency if it occurs in the spine [15][16][17].
  • Growth Faltering: Chronic anemia can rob a child of the energy needed for normal growth and puberty. Starting regular transfusions early enough can often help a child reach their full height potential [3][11].

Regardless of the current label, the focus of care is always on balancing the benefits of transfusions with the need to monitor for complications like iron overload, which can happen in both TDT and NTDT patients [18][19].

Common questions in this guide

What is the difference between TDT and NTDT in hemoglobin E-beta-thalassemia?
Transfusion-dependent thalassemia (TDT) means a person needs regular blood transfusions, often every 2 to 4 weeks, to support survival, growth, and health. Non-transfusion-dependent thalassemia (NTDT) means regular lifelong transfusions are not needed, although transfusions may still be necessary during illness, pregnancy, surgery, or rapid growth.
Can someone with HbE/beta-thalassemia change from NTDT to TDT?
Yes, the classification can change over time. It is based on how anemia affects the person, not on genetics alone; worsening anemia, increased transfusion needs, poor growth, bone changes, symptoms, or an enlarged spleen may lead the care team to recommend regular transfusions.
When might a person with NTDT need an occasional transfusion?
People with NTDT may need blood during a severe infection or other serious illness, pregnancy, major surgery, or rapid growth and puberty. The treating team makes this decision based on hemoglobin, symptoms, and the body's ability to meet oxygen needs.
What signs suggest that anemia is not being adequately controlled without regular transfusions?
Important signs can include increasing fatigue or shortness of breath, poor growth or delayed puberty, bone or facial changes, and an enlarging spleen. Doctors also follow hemoglobin over time and look for evidence that the bone marrow is working too hard.
Why can undertransfusion cause bone changes or extramedullary hematopoiesis?
When the bone marrow cannot make enough red blood cells, it expands and may thin or reshape bones. The body may also make blood-forming tissue outside the marrow, including near the spine; pressure on spinal nerves can cause back pain, numbness, or leg weakness and requires urgent medical attention.
How do doctors decide whether a child should receive regular transfusions?
They consider hemoglobin levels and trends, symptoms, spleen size, growth and development, bone changes, and the age when symptoms began. The Mahidol or Thai score may help describe severity, but it is not a universal rule; the decision is individualized.
Do both TDT and NTDT carry a risk of iron overload?
Yes. Iron overload can occur in both TDT and NTDT, so people with either pattern need a monitoring plan with their care team.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Hemoglobin E-beta-thalassemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How are we using clinical symptoms, such as fatigue and bone changes, alongside hemoglobin levels to make decisions about transfusion?
  2. 2.At what hemoglobin level would you consider my child 'too anemic' for an NTDT approach, and what symptoms should I watch for?
  3. 3.Are there signs of 'marrow overactivity' in my child's recent X-rays or physical exams, such as changes in facial bone structure or an enlarging spleen?
  4. 4.If we stay on an NTDT path, how often will we monitor for 'silent' complications like iron overload or low bone density?
  5. 5.What specific 'triggers' would move my child from an NTDT classification to TDT?

References

References (19)
  1. 1

    Clinical Classification, Screening and Diagnosis for Thalassemia.

    Viprakasit V, Ekwattanakit S

    Hematology/oncology clinics of North America 2018; (32(2)):193-211 doi:10.1016/j.hoc.2017.11.006.

    PMID: 29458726
  2. 2

    New therapeutic targets in transfusion-dependent and -independent thalassemia.

    Cappellini MD, Motta I

    Hematology. American Society of Hematology. Education Program 2017; (2017(1)):278-283 doi:10.1182/asheducation-2017.1.278.

    PMID: 29222267
  3. 3

    The Effect of Blood Transfusion on Growth of Patients with Hb E/β-Thalassemia.

    Chuansumrit A, Sirachainan N, Kitpoka P, et al.

    Hemoglobin 2019; (43(4-5)):264-272 doi:10.1080/03630269.2019.1692863.

    PMID: 31760834
  4. 4

    Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.

    Betts M, Flight PA, Paramore LC, et al.

    Clinical therapeutics 2020; (42(2)):322-337.e2 doi:10.1016/j.clinthera.2019.12.003.

    PMID: 31882227
  5. 5

    Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment.

    Inati A, Noureldine MA, Mansour A, Abbas HA

    BioMed research international 2015; (2015()):813098 doi:10.1155/2015/813098.

    PMID: 25834825
  6. 6

    Characterization and Clinical Assessment of a Peculiar Case of Hemolytic Anemia.

    Castelgrande F, Viola G, Calabrese C, et al.

    Journal of hematology 2024; (13(3)):108-115 doi:10.14740/jh1204.

    PMID: 38993732
  7. 7

    Genetic polymorphisms of HbE/beta thalassemia related to clinical presentation: implications for clinical diversity.

    Azman NF, Abdullah WZ, Hanafi S, et al.

    Annals of hematology 2020; (99(4)):729-735 doi:10.1007/s00277-020-03927-5.

    PMID: 32078010
  8. 8

    Genetic Mutations and Clinical Severity in Hemoglobin E/Beta-Thalassemia Patients in Bangladesh.

    Mahzabin N, Islam IA, Dey M, et al.

    Cureus 2026; (18(6)):e111264 doi:10.7759/cureus.111264.

    PMID: 42488279
  9. 9

    Mahidol Scoring for Assessing Various Grades of β Thalassemia Intermedia.

    Mannan J, Naveed M, Ahdi SG

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2019; (29(7)):635-638 doi:10.29271/jcpsp.2019.07.635.

    PMID: 31253214
  10. 10

    Risk Stratification-Based Therapy for Children with E-beta Thalassemia: A 20-Year Follow-Up Study.

    Ganesan K, Duraisamy S, Nair A, et al.

    Indian pediatrics 2025; (62(7)):506-510 doi:10.1007/s13312-025-00089-3.

    PMID: 40418380
  11. 11

    Clinico-Hematological Profile and Management of Children With Non-Transfusion Dependent Thalassemia (NTDT) at a Pediatric Center in Northern India.

    Parakh N, Khan A, Sharma S, Chandra J

    Indian pediatrics 2023; (60(8)):644-647.

    PMID: 37563885
  12. 12

    Epidemiologic study of major complications in adolescent and adult patients with thalassemia in Northeastern Thailand: the E-SAAN study phase I.

    Teawtrakul N, Jetsrisuparb A, Pongudom S, et al.

    Hematology (Amsterdam, Netherlands) 2018; (23(1)):55-60 doi:10.1080/10245332.2017.1358845.

    PMID: 28759343
  13. 13

    Prevalence of low bone mass among adolescents with nontransfusion-dependent hemoglobin E/β-thalassemia and its relationship with anemia severity.

    Nakavachara P, Petchkul J, Jeerawongpanich K, et al.

    Pediatric blood & cancer 2018; (65(1)) doi:10.1002/pbc.26744.

    PMID: 28801997
  14. 14

    Three-Dimensional Craniofacial Characteristics in Transfusion-Dependent and Non-Transfusion-Dependent Thalassemia Patients.

    Tekeli D, Ozturk Z, Özsoy U, et al.

    Journal of pediatric hematology/oncology 2026; (48(6)):e232-e240 doi:10.1097/MPH.0000000000003237.

    PMID: 42330112
  15. 15

    Cortical bone invasion in non-transfusion-dependent thalassemia: tumefactive extramedullary hematopoiesis reviewed.

    Masrouha KZ, Wazen J, Haddad A, et al.

    La Radiologia medica 2016; (121(8)):626-34 doi:10.1007/s11547-016-0638-1.

    PMID: 27108419
  16. 16

    Morbidities in non-transfusion-dependent thalassemia.

    Saliba AN, Taher AT

    Annals of the New York Academy of Sciences 2016; (1368(1)):82-94 doi:10.1111/nyas.13083.

    PMID: 27186941
  17. 17

    Beyond the blood: A practical guide to thalassemia care in the emergency department.

    Mufarrij A, Hodroj MH, Charbel N, et al.

    Blood reviews 2025; (74()):101327 doi:10.1016/j.blre.2025.101327.

    PMID: 40769855
  18. 18

    Iron overload in thalassemia: different organs at different rates.

    Taher AT, Saliba AN

    Hematology. American Society of Hematology. Education Program 2017; (2017(1)):265-271 doi:10.1182/asheducation-2017.1.265.

    PMID: 29222265
  19. 19

    Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.

    Sleiman J, Tarhini A, Bou-Fakhredin R, et al.

    International journal of molecular sciences 2018; (19(1)) doi:10.3390/ijms19010182.

    PMID: 29316681

This page is for informational purposes only and does not constitute medical advice. Discuss hemoglobin trends, symptoms, and transfusion decisions with your hematology team.